Navigation Links
InteRNA Technologies Announces Establishment of Scientific Advisory Board
Date:7/8/2010

UTRECHT, the Netherlands, July 8, 2010 /PRNewswire/ -- InteRNA Technologies B.V., a biopharmaceutical company focusing on the development of intelligent microRNA (miRNA)-based therapeutics for cancer, announces the establishment of its Scientific Advisory Board (SAB). The SAB will further guide the Company in the development of cancer therapies based on the unique functions of its proprietary miRNAs.

The SAB is chaired by Emile E. Voest, MD, PhD, Professor of Medical Oncology at the Department of Medical Oncology, UMC Utrecht, the Netherlands.

    Other distinguished members are:

    - Jaap Verweij, MD, PhD, Professor of Medical Oncology at the Department.
      of Medical Oncology at Erasmus MC-Daniel den Hoed Cancer Center,
      Rotterdam, the Netherlands;

    - William C. Hahn, MD, PhD, Associate Professor of Medicine, Harvard
      Medical School, Dana-Farber Cancer Institute and Senior Associate
      Member at the Broad Institute of Harvard and MIT, Boston, USA;

    - Allan Balmain, PhD, FRSE, Barbara Bass Bakar Distinguished Professor in
      Cancer Genetics at UCSF Helen Diller Family Comprehensive Cancer
      Center, San Francisco, USA;

    - Graham Dixon, PhD, Sr. VP Drug Discovery, Galapagos NV, Mechelen,
      Belgium;

    - Edwin Cuppen, PhD, scientific co-founder of InteRNA Technologies, and
      Professor of Genome Biology at Utrecht University, Professor of Human
      Genetics and head of the Research section of the Department of Medical
      Genetics, UMC Utrecht and staff scientist at Hubrecht Institute,
      Utrecht, the Netherlands;

    - Eugene Berezikov, PhD, scientific co-founder of InteRNA Technologies
      and staff scientist at Hubrecht Institute, the Netherlands.

"We are very pleased with the formation of our SAB and feel honored to collaborate with this experienced team that is highly committed advising the Company on moving forward its research and development towards the clinic", said Roel Schaapveld, CEO of InteRNA Technologies. "The complementary knowledge of the renowned clinicians and scientists in this team will play a significant role in our R&D programs and success of the Company."

Edwin Cuppen, scientific co-founder of InteRNA Technologies, commented: "While fundamental research has now unequivocally demonstrated the importance of miRNA's in regulation and deregulation of biological processes, InteRNA Technologies has in the past few years build up a unique position in converting this knowledge into miRNA-based cancer treatment strategies. These activities are now further supported by a wealth of knowledge and expertise through this SAB, which will undoubtedly further accelerate the path towards miRNA-based drugs."

About InteRNA Technologies B.V.

InteRNA Technologies B.V. actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The company's primary focus is to unravel the role of its proprietary miRNAs in cancer.

InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and has established close relationships with the research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute (Utrecht, the Netherlands), leading scientific groups in the field of miRNA research.

See for more information http://www.interna-technologies.com.


'/>"/>
SOURCE InteRNA Technologies B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017 RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Japan Patent Office (JPO) for the composition ... factor (CTGF) for the treatment or prevention of ... fibrosis and proliferative retinopathy (Japanese Patent #: 6060071).  ...
(Date:3/28/2017)... 2017 The global flow ... billion by 2025, according to a new study by ... diseases and cancer is expected to upsurge the demand ... the coming years. In addition, higher number of physicians ... stem cell therapy, due to adverse effects caused by ...
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... MA (PRWEB) , ... March 28, 2017 , ... ... for direct measurement of corrosive ions found in power plant water and steam. ... components such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. ...
(Date:3/28/2017)... ... 2017 , ... A minimally invasive porcelain veneer is increasing ... Association of Dental Laboratories (NADL) is informing dentists about the benefits of minimally ... dental laboratories and technicians that create these veneers. , According to National ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... ... Thank you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium ... providers and offered an opportunity to collaborate and network with healthcare colleagues across the ... attendees gathered for a lively discussion on trends and issues that healthcare leaders will ...
Breaking Medicine News(10 mins):